Philadelphia positive chronic myeloid leukaemia – Diagnostics – Overview of Information and Clinical Research

Philadelphia chromosome-positive chronic myeloid leukemia is diagnosed through specific blood and bone marrow tests that detect a genetic abnormality where pieces of chromosomes 9 and 22 swap positions. Understanding what tests you need and when to seek them can help ensure an accurate diagnosis and the right treatment path for this slowly progressing blood cancer.

Introduction: Who Should Undergo Diagnostics

Knowing when to seek medical attention is the first step toward identifying Philadelphia chromosome-positive chronic myeloid leukemia. Sometimes this form of leukemia, often shortened to Ph+ CML, causes no symptoms at all in its early stages. Many people discover they have it during a routine blood test ordered for an unrelated reason. This makes regular health checkups particularly important, especially for older adults, as CML typically occurs during or after middle age and rarely affects children.^[1]^[2]

You should consider seeking diagnostic testing if you experience certain persistent symptoms. These warning signs include feeling extremely tired for no clear reason, unexplained weight loss, drenching night sweats that soak your clothes or bedding, fever without an obvious infection, or pain or a feeling of fullness below your ribs on the left side. This last symptom often results from an enlarged spleen, which happens when abnormal white blood cells collect in this organ.^[2]^[6]

If you notice any combination of these symptoms lasting more than a few weeks, it’s advisable to make an appointment with your healthcare provider. Chronic myeloid leukemia progresses more slowly than other forms of leukemia, which means catching it early gives you more time to plan treatment. However, because the symptoms can be vague and similar to many other conditions, people sometimes delay seeking help, thinking they’re just tired or stressed. Trust your instincts—if something feels wrong with your health, it’s worth getting checked.^[2]

People who have been exposed to very high levels of radiation in the past face a higher risk of developing CML and should be particularly vigilant about symptoms. Older individuals and men also have slightly elevated risk. However, it’s important to understand that CML is not passed from parent to child, so having a family member with the condition does not automatically increase your risk.^[6]^[7]

Classic Diagnostic Methods

Once you visit your doctor with concerns, the diagnostic process for Philadelphia chromosome-positive chronic myeloid leukemia typically begins with straightforward tests before moving to more specialized examinations. Your healthcare provider will start with a physical examination, checking your vital signs like pulse and blood pressure. They will carefully feel your lymph nodes, spleen, and abdomen to detect any swelling. An enlarged spleen is one of the most common physical findings when CML is diagnosed, though in about 10% of cases the spleen shows no enlargement at all.^[8]^[13]

The next step involves blood tests. The most important initial blood test is called a complete blood count, often abbreviated as CBC. This test measures the number of different types of cells in your blood. In people with CML, the CBC typically reveals a very high number of white blood cells. The presence of too many white blood cells in the bloodstream is one of the hallmark signs of this disease. Blood tests can also measure how well your organs are functioning, which helps doctors understand if the leukemia has affected other parts of your body.^[6]^[7]

If your blood tests suggest leukemia, your doctor will order bone marrow tests to confirm the diagnosis. The bone marrow is the soft, spongy tissue inside your bones where blood cells are made. There are two types of bone marrow tests, and they are usually performed together. In a bone marrow aspiration, your doctor uses a thin needle to remove a small amount of the liquid part of your bone marrow. In a bone marrow biopsy, a needle removes a small piece of solid bone tissue along with the marrow inside. Both samples are typically taken from the back of your hip bone. These samples are then sent to a laboratory where specialists examine them under a microscope to look for abnormal cells.^[6]^[13]

⚠️ Important

Bone marrow tests might sound frightening, but they are essential for accurate diagnosis. The procedure is done with local anesthesia to minimize discomfort. While you may feel pressure during the test, most people tolerate it well and the entire process takes only about 10 to 20 minutes.

The most critical diagnostic test for Ph+ CML involves looking for the Philadelphia chromosome itself. This chromosome is an abnormality that occurs when part of chromosome 9 breaks off and attaches to chromosome 22, creating an unusual genetic structure. Specialized genetic tests can detect this abnormality. One such test is called fluorescence in situ hybridization, or FISH analysis. These tests examine your blood or bone marrow samples to see if the characteristic swap between chromosomes 9 and 22 has occurred. The Philadelphia chromosome is present in more than 90% of people with CML, making it an extremely reliable diagnostic marker.^[1]^[6]^[13]

When the Philadelphia chromosome forms, it creates an abnormal gene called BCR-ABL. This gene produces a protein called tyrosine kinase, which acts like a faulty switch that tells your bone marrow to make too many white blood cells. Laboratory tests can detect both the BCR-ABL gene itself and the abnormal protein it produces. Finding this gene confirms the diagnosis of Philadelphia chromosome-positive chronic myeloid leukemia and distinguishes it from other types of leukemia that might look similar but require different treatments.^[1]^[9]

Sometimes additional imaging tests might be ordered, though they are not always necessary for diagnosis. A computed tomography scan, or CT scan, might be used to check if your spleen is enlarged or to look at other organs in your abdomen. These scans create detailed three-dimensional images of the inside of your body. However, unlike some other cancers, CML doesn’t usually require extensive imaging because it primarily affects the blood and bone marrow rather than forming solid tumors.^[12]

Your doctor may also want to understand which phase of CML you have. Unlike many cancers that are described in stages, CML is classified into three phases: chronic phase, accelerated phase, and blast phase. The phase is determined by how many immature white blood cells, called blasts, are present in your blood and bone marrow. Most people—about 90%—are diagnosed in the chronic phase, when the disease is progressing slowly and is easier to manage. The phase of your disease helps guide treatment decisions and gives your doctor information about your prognosis.^[1]^[4]

Diagnostics for Clinical Trial Qualification

If you or your doctor are considering participation in a clinical trial for Philadelphia chromosome-positive chronic myeloid leukemia, you will need to undergo additional or more frequent diagnostic tests. Clinical trials are research studies that test new treatments to see if they work better than existing options. These studies have strict eligibility requirements to ensure that participants are appropriate for the experimental treatment being studied and that results can be accurately measured.

The first requirement for entering a CML clinical trial is confirmation that you have the Philadelphia chromosome. Trials specifically designed for Ph+ CML will require genetic testing that clearly demonstrates the presence of the BCR-ABL gene fusion. This is typically done through the same tests used for initial diagnosis, such as FISH analysis or other molecular techniques that can detect the 9;22 chromosome translocation. Some trials may require these tests to be repeated or performed at a specific certified laboratory to ensure standardization across all study participants.^[6]^[12]

Clinical trials often specify which phase of CML they are studying. If a trial is designed for chronic-phase CML, you will need blood and bone marrow tests that confirm you are in this phase and not in accelerated or blast phase. The tests will count the percentage of blast cells in your samples. For chronic phase, blast cells typically make up less than 10% of the cells in your blood and bone marrow. For accelerated phase, blasts account for 10% to 19%, and for blast phase, they represent 20% or more. These percentages are critical for trial eligibility.^[8]

Many clinical trials require baseline measurements that will be used to compare how well the experimental treatment works. This means you might need comprehensive blood tests to establish your starting white blood cell count, red blood cell count, and platelet count. Your liver and kidney function will also be tested to ensure these organs are working well enough to handle the study medication. Some trials exclude people whose organs aren’t functioning above a certain threshold because the medication might be too risky for them.^[12]

Trials may also require specific molecular monitoring tests. One common requirement is measuring your BCR-ABL transcript levels using a highly sensitive laboratory technique. This test quantifies exactly how much of the abnormal BCR-ABL gene is active in your body. Researchers use this as a way to track how effectively the treatment is reducing the leukemia cells over time. You might need this test before starting the trial and then at regular intervals throughout the study—often every three months—to monitor your response to treatment.

Some clinical trials are designed for people who have already tried other CML treatments that didn’t work well enough or caused intolerable side effects. If you’re considering such a trial, you’ll need documentation of your previous treatments and why they failed. This might include records showing that your BCR-ABL levels didn’t decrease sufficiently, that your disease progressed to a more advanced phase, or that you developed resistance mutations—genetic changes that make the leukemia cells immune to certain medications.

⚠️ Important

Participating in a clinical trial often means more frequent testing and monitoring than standard care. While this requires extra time and commitment, it also means your health is being watched very closely by a dedicated medical team. Ask your clinical trial coordinator about the testing schedule before you commit so you can plan accordingly.

Physical examinations are another standard requirement for clinical trial enrollment. Researchers need to document your overall health status, including measuring the size of your spleen if it’s enlarged. They’ll record your weight, blood pressure, and other vital signs. These measurements establish a baseline that helps researchers determine if the experimental treatment causes any unexpected side effects or changes to your body during the study.

Age, pregnancy status, and other medical conditions can affect clinical trial eligibility. While these aren’t diagnostic tests in the traditional sense, you may need tests to verify certain information. For example, women of childbearing age typically need a pregnancy test before enrolling because many cancer treatments can harm an unborn baby. People with certain heart conditions might need an electrocardiogram to assess their heart function before starting a medication that could affect the heart.

Throughout the clinical trial, diagnostic testing continues at scheduled intervals. You’ll have regular blood draws to monitor your blood cell counts and organ function. You might have bone marrow tests repeated at specific time points to see how the treatment is affecting the leukemia cells in your marrow. These repeated tests serve two purposes: they help ensure your safety by catching any dangerous side effects early, and they provide data that researchers use to determine whether the experimental treatment is effective.

Prognosis and Survival Rate

Prognosis

The outlook for people with Philadelphia chromosome-positive chronic myeloid leukemia has improved dramatically over the past two decades. Several factors influence how the disease will progress and how well treatment will work. The most important factor is the phase of CML at diagnosis. Most people are diagnosed in the chronic phase, when the disease progresses slowly and is generally easier to control. If you’re diagnosed in this phase, your doctor might tell you that with proper treatment, you can expect to live about as long as people without CML.^[16]

Taking your medication exactly as prescribed is one of the strongest predictors of good outcomes. CML is treated with medicines called tyrosine kinase inhibitors, and when people take these drugs correctly every day, the disease typically remains well-controlled for many years. Age also affects prognosis—people younger than 60 generally have better outcomes than older adults. The size of your spleen at diagnosis matters too. A significantly enlarged spleen suggests a less favorable prognosis than a normal or minimally enlarged spleen.^[16]

Your blood test results at diagnosis provide important prognostic information. Having either a very low or very high platelet count indicates a less favorable outlook. The presence of additional genetic abnormalities beyond the Philadelphia chromosome can increase the risk that the disease will progress from one phase to another or that it won’t respond well to treatment. Doctors sometimes use scoring systems that combine multiple prognostic factors to estimate how well you’re likely to respond to treatment.^[16]

How quickly you achieve certain treatment milestones also predicts long-term outcomes. If treatment successfully reduces your BCR-ABL levels within the first few months, this is a very positive sign. Conversely, if early response to treatment isn’t achieved, outcomes tend to be less favorable. Some people eventually progress from chronic phase to accelerated or blast phase, which are more aggressive forms of CML that are harder to control. However, modern treatments have significantly reduced the likelihood of this progression.^[4]

Survival Rate

Survival rates for Philadelphia chromosome-positive chronic myeloid leukemia have improved remarkably since the introduction of targeted medications in the early 2000s. Today, most people diagnosed with chronic-phase CML can achieve what doctors call remission, where the disease is controlled and not causing symptoms. Many patients live for many years after diagnosis with a near-normal life expectancy.^[2]

The five-year survival rate—meaning the percentage of people still alive five years after diagnosis—has increased substantially with modern treatments. However, statistics vary depending on which phase of CML someone has at diagnosis and how well they respond to initial treatment. It’s important to remember that approximately 30% of patients do not survive five years, which highlights that despite available treatments, there are still patients who face challenges with disease control.^[4]

People diagnosed in chronic phase have significantly better survival rates than those diagnosed in accelerated or blast phase. About 90% of CML patients are diagnosed in chronic phase, giving most people a favorable starting point. Those in blast phase face much more difficult circumstances because this phase resembles acute leukemia, progresses quickly, and is harder to treat effectively.^[4]

It’s worth noting that survival statistics are based on large groups of people and represent averages. Your individual outcome depends on many personal factors including the specific characteristics of your disease, your age and overall health, how you respond to treatment, and how consistently you take your medication. Your healthcare team can provide more personalized information based on your specific situation.

#1 Clinical Trials Search in Europe